Upload
jessie-hartgrove
View
230
Download
1
Embed Size (px)
Citation preview
R5洪逸平SUPERVISOR 趙大中醫師
Breast Cancer
The most prevalent cancer in female
Mortality 4th in Taiwan
Treatment of Breast Cancer
Breast Cancer
When to change regimen? Unacceptable toxicity Progression disease
Current Tools for Follow-up
Radiologic image Standard serologic test Circulating soluble-tumor–associated
protein biomarkers Circulation tumor cells Circulating tumor DNA
Radiologic image
Expensive Time consuming Inconvenient Inconclusive May not informative in several months Reasonably sensitive, not always reflect
tumor response or progression
Standard serologic test
Such as AST and ALT, LDH Inaccurate
Circulating soluble-tumor–associated protein biomarkers
CEA, CA 15-3 CA 15-3, soluble forms of MUC(cell surface associated )-1 protein
J Clin Oncol 2007 25:5287-5312.
Circulation tumor cells
In 2004, pts with fewer CTC lived longer than with more CTCN Engl J Med 351(8):781–791.
177 Pts with metastatic breast cancer
Annals of Oncology 22: 86–92, 2011
CTCs and tumor markers in Breast Cancer
IC 2006-04 enrolled prospectively 267 metastatic breast cancer pts.
Breast Cancer Research 2012, 14:R29
Circulation tumor DNA
Circulating tumor DNA
In a study in China, 46 of 126 primary breast cancer pts have p53 mutation in the peripheral blood
Clin Cancer Res 2001;7:2222-2227
Circulating tumor DNA
Specific mutation and structural variation in primary tumor cell
142 breast cancer pts ( not disseminated) was analyzed at diagnosis
Clin Cancer Res 2002;8:3761-3766.
Method
Prospective, single-center study Compare circulating tumor DNA, CA 15-3,
circulating tumor cell Tagged-amplicon deep sequencing for PIK3CA
(encoding the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha protein) and TP53 (encoding tumor protein p53) or paired-end whole-genome sequencing p53 mutations are found in 50–75% of breast
carcinoma patients Serial blood samples(30ml) every 3 or more
weeks
Science (Wash. DC), 253: 49–53, 1991.
Identification of Genome Alteration
Tagged-amplicon deep sequencing
Paired-end whole-genome sequencing
22 3 5mutation SV
CA 15-3 vs ctDNA
CTCs and ctDNA
Result
Result
Result
Quartiles of ctDNA and OS
ctDNA, CTCs and Relative Hazard
Conclusion
Circulating tumor DNA shows superior sensitivity and has a greater dynamic range that correlates with tumor burden
Circulating tumor DNA provide earliest measure of treatment response
Identification of somatic alteration is needed Target sequencing could be expanded in addition
to PIK3CA and TP53 when the cost reduced There are many ways to identify tumor DNA :
digital PCR assay, targeted deep sequencing, exome sequencing, BEAMing, Safe-SeqS…
Future
Target like BCR/ABL may be found and develop new target therapy!!
Thanks for Your Attention!!